Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. / van de Wall, Stephanie; Santegoets, Kim; van Houtum, Eline; Büll, Christian; Adema, Gosse.
I: Trends in Immunology, Bind 41, Nr. 4, 2020, s. 274-285.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
AU - van de Wall, Stephanie
AU - Santegoets, Kim
AU - van Houtum, Eline
AU - Büll, Christian
AU - Adema, Gosse
PY - 2020
Y1 - 2020
N2 - Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor cells and have emerged as potent regulatory molecules involved in creating a tumor-supportive microenvironment. Sialoglycans can be recognized by sialic acid-binding immunoglobulin-like lectins (Siglecs), a family of immunomodulatory receptors. Most mammalian Siglecs transmit inhibitory signals comparable with the immune checkpoint inhibitor programmed death protein 1 (PD-1), but some are activating. Recent studies have shown that tumor cells can exploit sialoglycan–Siglec interactions to modulate immune cell function, contributing to an immunosuppressive tumor microenvironment (TME). Interference with sialoglycan synthesis or sialoglycan–Siglec interactions might improve antitumor immunity. Many questions regarding specificity, signaling, and regulatory function of sialoglycan–Siglec interactions remain. We posit that sialoglycans and Siglecs present as potential glyco-immune ‘checkpoints’ for cancer immunotherapy.
AB - Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor cells and have emerged as potent regulatory molecules involved in creating a tumor-supportive microenvironment. Sialoglycans can be recognized by sialic acid-binding immunoglobulin-like lectins (Siglecs), a family of immunomodulatory receptors. Most mammalian Siglecs transmit inhibitory signals comparable with the immune checkpoint inhibitor programmed death protein 1 (PD-1), but some are activating. Recent studies have shown that tumor cells can exploit sialoglycan–Siglec interactions to modulate immune cell function, contributing to an immunosuppressive tumor microenvironment (TME). Interference with sialoglycan synthesis or sialoglycan–Siglec interactions might improve antitumor immunity. Many questions regarding specificity, signaling, and regulatory function of sialoglycan–Siglec interactions remain. We posit that sialoglycans and Siglecs present as potential glyco-immune ‘checkpoints’ for cancer immunotherapy.
U2 - 10.1016/j.it.2020.02.001
DO - 10.1016/j.it.2020.02.001
M3 - Journal article
C2 - 32139317
VL - 41
SP - 274
EP - 285
JO - Trends in Immunology
JF - Trends in Immunology
SN - 1471-4906
IS - 4
ER -
ID: 237092634